The Choroid after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy

Acta Medica (Hradec Kralove). 2022;65(3):89-98. doi: 10.14712/18059694.2022.24.

Abstract

Purpose: To characterize choroidal structure and vasculature after half-dose verteporfin photodynamic therapy (hd-vPDT) in eyes with chronic central serous chorioretinopathy using Enhanced Depth Imaging Optical Coherence Tomography (EDI OCT) and Optical Coherence Tomography Angiography (OCT-A).

Methods: This prospective case-control study included 10 eyes. Choroid was examined before and at 1 month following hd-vPDT. We measured choroidal thickness (CT) at subfoveal area and at 750 μm nasal and temporal of fovea and thickness of Haller and choriocapillaris/Sattler layers. Whole (WA), luminal (LA) and interstitial area (IA) at EDI-OCT, and perfusion density at OCT-A were analyzed. The unaffected fellow eyes were used for comparisons.

Results: Mean CT at subfoveal area and at 750 μm nasal and temporal of fovea, values of Haller and choriocapillaris/Sattler layers and those of WA, LA and IA were reduced, while PD increased at 1 month after hd-vPDT (all p < 0.001). There was a significant (p < 0.05) negative correlation (ρ = -0.658) between PD and post-treatment logMARVA. None of analyzed parameters reached values of unaffected fellow eye.

Conclusion: Following hd-vPDT, choroidal thickness with both luminal and interstitial components markedly decreased, while perfusion of choriocapillaris improved.

Keywords: PDT; chronic central serous chorioretinopathy; enhanced depth imaging; half-dose photodynamic therapy; optical coherence tomography; optical coherence tomography angiography.

MeSH terms

  • Case-Control Studies
  • Central Serous Chorioretinopathy* / drug therapy
  • Choroid / blood supply
  • Choroid / diagnostic imaging
  • Chronic Disease
  • Fluorescein Angiography / methods
  • Humans
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Retrospective Studies
  • Tomography, Optical Coherence / methods
  • Verteporfin / therapeutic use
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Verteporfin